Amezalpat

N/A

Report date: 2025/06/10 17:01:41
NME

Base Information

Drug NameAmezalpat
Drug Alias NameTPST-1120
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α antagonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNew Zealand +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTempest Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTempest Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A